Palisade Bio, Inc. PALI

Overview

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, focused on developing innovative therapeutics designed to protect the integrity of the intestinal barrier. Their efforts are rooted in addressing medical conditions related to the digestive system, with an emphasis on improving postoperative recovery processes and minimizing complications stemming from surgeries. The company collaborates closely with key academic institutions and industry partners, such as the Regents of the University of California and Newsoara Biopharma Co., Ltd., to advance their research and development objectives. Through these strategic partnerships, Palisade Bio, Inc. aims to bring groundbreaking treatments to market that can significantly enhance patient outcomes in the United States.

Products and Services

• LB1148

Palisade Bio's flagship product, LB1148, represents a pioneering therapeutic approach in the realm of gastrointestinal surgery recovery. It is an oral liquid formulation of the enzyme inhibitor tranexamic acid, specifically designed to mitigate the formation of postoperative adhesions and accelerate the return of bowel function in adults following surgery. By targeting the digestive process, LB1148 not only aims to reduce the occurrence of postoperative ileus—a common and debilitating complication after abdominal surgery—but also facilitates a quicker and more comfortable recovery for patients. This product underscores Palisade Bio's commitment to improving surgical outcomes and patient quality of life through innovative biopharmaceutical solutions.